24/7 Market News Snapshot 01 May, 2025 – Olo Inc. (NYSE:OLO)

May 1, 2025

DENVER, Colo., 01 May, 2025 (www.247marketnews.com) – (NYSE:OLO) are discussed in this article.
Olo Inc. (NYSE:OLO) has seen a remarkable increase in stock value, opening at $6.90 and rising approximately 15.24% to currently trade at $7.145. This surge in investor interest is reflected in a substantial trading volume of 4.10 million shares, indicating a positive market sentiment that may be linked to specific developments within the company. As Olo’s stock demonstrates strong bullish momentum, potential resistance levels are anticipated to emerge above $7.50. Investors are advised to closely monitor trading volumes, as sustained activity could reinforce this upward trend, while significant pullbacks may suggest profit-taking among shareholders.

In a parallel development, Kura Oncology, Inc. has reached a significant milestone by submitting a New Drug Application (NDA) for ziftomenib to the U.S. Food and Drug Administration (FDA). This application, submitted on March 31, 2025, proposes ziftomenib as a new treatment for adult patients with relapsed or refractory acute myeloid leukemia (AML) who possess an NPM1 mutation. The NDA submission has triggered a $45 million milestone payment under Kura’s global collaboration with Kyowa Kirin Co., Ltd., highlighting their joint commitment to advancing cancer treatment options.

The pivotal data from the Phase 2 registration-directed trial (KOMET-001) will be showcased in an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, reinforcing Kura’s dedication to sharing significant research findings. Additionally, the initiation of a Phase 1 clinical trial to assess ziftomenib combined with imatinib for advanced gastrointestinal stromal tumors (GIST) exemplifies the therapy’s potential across various cancer types.

With pro forma cash reserves around $703.2 million, complemented by anticipated collaboration payments, Kura is well-prepared to advance the ziftomenib program and support vital developmental stages. The company’s robust pipeline and financial health position it as a key player in the biopharmaceutical sector, poised for an impactful year ahead.

Related news for (OLO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.